Intellia Therapeutics (LTS:0JBU) Other Current Payables: $0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JBU Intellia Therapeutics Inc LTS:0JBU
63 GF Score
Price $11.20
GF Value $21.20
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Intellia Therapeutics Other Current Payables?

Intellia Therapeutics LTS:0JBU -3.28% 63 Other Current Payables is $0.00 Mil as of Mar. 2026. GuruFocus rates LTS:0JBU with a GF Score™ of 63/100 and a GF Value™ of $21.20 (Possible Value Trap). The stock has 5 warning signs investors should review.

Intellia Therapeutics's Other Current Payables for the quarter that ended in Mar. 2026 was $0.00 Mil.

Intellia Therapeutics Other Current Payables Related Terms

Intellia Therapeutics Other Current Payables Historical Data

* Premium members only.

The historical data trend for Intellia Therapeutics's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intellia Therapeutics Other Current Payables Chart

Intellia Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Intellia Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0JBU
63GF Score
Intellia Therapeutics Inc LTS:0JBU
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intellia Therapeutics Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of $0.00 Mil mean?
Intellia Therapeutics (LTS:0JBU) has a Other Current Payables of $0.00 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Intellia Therapeutics and its competitors.
Is Intellia Therapeutics' Other Current Payables too high?
Intellia Therapeutics' current Other Current Payables is $0.00 Mil. Overall, Intellia Therapeutics has a GF Score™ of 63/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Intellia Therapeutics' Other Current Payables compare to MLYS and VCEL?
Intellia Therapeutics' Other Current Payables of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Intellia Therapeutics and its competitors. Intellia Therapeutics's current Other Current Payables is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intellia Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Intellia Therapeutics (LTS:0JBU) is currently considered Possible Value Trap. The stock's GF Value™ is $21.20, compared to a current price of $11.20 — trading 47.2% below its estimated fair value. The current Other Current Payables is $0.00 Mil. Intellia Therapeutics' overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Intellia Therapeutics (LTS:0JBU), the current Other Current Payables is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intellia Therapeutics (LTS:0JBU) Overvalued in 2026?

Based on GuruFocus' analysis, Intellia Therapeutics stock appears to be undervalued. The current stock price of $11.20 is trading 47.2% below its estimated GF Value™ of $21.20. GuruFocus considers Intellia Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0JBU:

  • Other Current Payables: $0.00 Mil
  • GF Value™: $21.20 vs. price of $11.20 (47.2% below fair value)
  • GF Score™: 63/100 with 5 warning signs

No single metric tells the full story. See the LTS:0JBU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intellia Therapeutics Business Description

Other Exchanges NTLA:USA38I:Germany
Address 40 Erie Street, Suite 130, Cambridge, MA, USA, 02139
Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
63GF Score

Get the complete analysis for LTS:0JBU

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.20
Price
$21.20
GF Value